On January 15, I found it very interesting that the CFO of Teva Pharmaceuticals (NASDAQ:TEVA) indicated that Teva had plans to return to a deal making strategy on the same day that Antares Pharma (NASDAQ:ATRS) announced the launch of OTREXUP. OTREXUP has a chance to be a transformational product for Antares, since it takes a well established rheumatoid arthritis drug in methotrexate, and changes the delivery method from an oral pill to a self administered subcutaneous injection. Subcutaneous injection not only allows for greater blood levels of medication than oral, but may also cut down on the gastrointestinal side effects from the oral medication. Given that Antares has taken the current standard of care drug...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|